Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC
European Journal of Cancer · 2026-12 · 249 · 117812
DOI: 10.1016/j.ejca.2026.117812 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-12. Verfasst von Constantin Rieger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany. Electronic addres…. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany. Electronic address: constantin.rieger@uk-koeln.de.
- Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany.
- Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Köln-Bonn, Cologne, Germany.
- Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany; Department of Urology, Medical University Vienna, Austria.
Zitieren
APA
Rieger, C., Heidenreich, J., Weiten, R., Nohl, E., Paffenholz, P., Storz, E., Pfister, D., & Heidenreich, A. (2026). Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC. European Journal of Cancer, 249, 117812. https://doi.org/10.1016/j.ejca.2026.117812
Vancouver
Rieger C, Heidenreich J, Weiten R, Nohl E, Paffenholz P, Storz E, et al. Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC. European Journal of Cancer. 2026;249:117812. doi:10.1016/j.ejca.2026.117812
BibTeX
@article{Rieger2026,
author = {Rieger, Constantin and Heidenreich, Julian and Weiten, Richard and Nohl, Elena and Paffenholz, Pia and Storz, Enno and Pfister, David and Heidenreich, Axel},
title = {Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC},
journal = {European Journal of Cancer},
year = {2026},
volume = {249},
pages = {117812},
doi = {10.1016/j.ejca.2026.117812}
}
EUVIMED